Integrated Analysis of Mismatch Repair System in Malignant Astrocytomas

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 Sep 28

PMID 24073290

Citations 10

Authors

Irene Rodriguez-Hernandez

Juan Luis Garcia

Angel Santos-Briz

Aurelio Hernandez-Lain

Jose Maria Gonzalez-Valero

Juan Antonio Gomez-Moreta

Oscar Toldos-Gonzalez

Juan Jesus Cruz

Javier Martin-Vallejo

Rogelio Gonzalez-Sarmiento

Affiliations

Soon will be listed here.

Abstract

Malignant astrocytomas are the most aggressive primary brain tumors with a poor prognosis despite optimal treatment. Dysfunction of mismatch repair (MMR) system accelerates the accumulation of mutations throughout the genome causing uncontrolled cell growth. The aim of this study was to characterize the MMR system defects that could be involved in malignant astrocytoma pathogenesis. We analyzed protein expression and promoter methylation of MLH1, MSH2 and MSH6 as well as microsatellite instability (MSI) and MMR gene mutations in a set of 96 low- and high-grade astrocytomas. Forty-one astrocytomas failed to express at least one MMR protein. Loss of MSH2 expression was more frequent in low-grade astrocytomas. Loss of MLH1 expression was associated with MLH1 promoter hypermethylation and MLH1-93G>A promoter polymorphism. However, MSI was not related with MMR protein expression and only 5% of tumors were MSI-High. Furthermore, the incidence of tumors carrying germline mutations in MMR genes was low and only one glioblastoma was associated with Lynch syndrome. Interestingly, survival analysis identified that tumors lacking MSH6 expression presented longer overall survival in high-grade astrocytoma patients treated only with radiotherapy while MSH6 expression did not modify the prognosis of those patients treated with both radiotherapy and chemotherapy. Our findings suggest that MMR system alterations are a frequent event in malignant astrocytomas and might help to define a subgroup of patients with different outcome.

Citing Articles

Emerging applications of hypomethylating agents in the treatment of glioblastoma (Review).

Silva-Hurtado T, Inocencio J, Yong R Mol Clin Oncol. 2024; 21(3):59.

PMID: 39006906 PMC: 11240870. DOI: 10.3892/mco.2024.2757.

Epigenetic preconditioning with decitabine sensitizes glioblastoma to temozolomide via induction of MLH1.

Gallitto M, Cheng He R, Inocencio J, Wang H, Zhang Y, Deikus G J Neurooncol. 2020; 147(3):557-566.

PMID: 32193690 PMC: 7256087. DOI: 10.1007/s11060-020-03461-4.

Genetic counseling and tumor predisposition in neuro-oncology practice.

Dunbar E, Eppolito A, Henson J Neurooncol Pract. 2019; 3(1):17-28.

PMID: 31579518 PMC: 6760343. DOI: 10.1093/nop/npv051.

Different behaviour of DVL1, DVL2, DVL3 in astrocytoma malignancy grades and their association to TCF1 and LEF1 upregulation.

Kafka A, Bacic M, Tomas D, Zarkovic K, Bukovac A, Njiric N J Cell Mol Med. 2018; 23(1):641-655.

PMID: 30468298 PMC: 6307814. DOI: 10.1111/jcmm.13969.

Prognostic value of MLH1 promoter methylation in male patients with esophageal squamous cell carcinoma.

Wu D, Chen X, Xu Y, Wang H, Yu G, Jiang L Oncol Lett. 2017; 13(4):2745-2750.

PMID: 28454461 PMC: 5403441. DOI: 10.3892/ol.2017.5759.

References

Alldinger I, Schaefer K, Goedde D, Ottaviano L, Dirksen U, Ranft A . Microsatellite instability in Ewing tumor is not associated with loss of mismatch repair protein expression. J Cancer Res Clin Oncol. 2007; 133(10):749-59. DOI: 10.1007/s00432-007-0220-2. View

Chen H, Taylor N, Sotamaa K, Mutch D, Powell M, Schmidt A . Evidence for heritable predisposition to epigenetic silencing of MLH1. Int J Cancer. 2007; 120(8):1684-8. DOI: 10.1002/ijc.22406. View

Mrkonjic M, Roslin N, Greenwood C, Raptis S, Pollett A, Laird P . Specific variants in the MLH1 gene region may drive DNA methylation, loss of protein expression, and MSI-H colorectal cancer. PLoS One. 2010; 5(10):e13314. PMC: 2954166. DOI: 10.1371/journal.pone.0013314. View

Huse J, Holland E . Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer. 2010; 10(5):319-31. DOI: 10.1038/nrc2818. View

Castrilli G, Fabiano A, La Torre G, Marigo L, Piantelli C, Perfetti G . Expression of hMSH2 and hMLH1 proteins of the human DNA mismatch repair system in salivary gland tumors. J Oral Pathol Med. 2002; 31(4):234-8. DOI: 10.1034/j.1600-0714.2002.310407.x. View

Wen P, Kesari S . Malignant gliomas in adults. N Engl J Med. 2008; 359(5):492-507. DOI: 10.1056/NEJMra0708126. View

Rass K, Gutwein P, Welter C, Meineke V, Tilgen W, Reichrath J . DNA mismatch repair enzyme hMSH2 in malignant melanoma: increased immunoreactivity as compared to acquired melanocytic nevi and strong mRNA expression in melanoma cell lines. Histochem J. 2002; 33(8):459-67. DOI: 10.1023/a:1014472314354. View

Srivastava T, Chattopadhyay P, Mahapatra A, Sarkar C, Sinha S . Increased hMSH2 protein expression in glioblastoma multiforme. J Neurooncol. 2004; 66(1-2):51-7. DOI: 10.1023/b:neon.0000013482.99032.b0. View

Watson P, Vasen H, Mecklin J, Bernstein I, Aarnio M, Jarvinen H . The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer. 2008; 123(2):444-449. PMC: 2627772. DOI: 10.1002/ijc.23508. View

10.

Belvederesi L, Bianchi F, Loretelli C, Gagliardini D, Galizia E, Bracci R . Assessing the pathogenicity of MLH1 missense mutations in patients with suspected hereditary nonpolyposis colorectal cancer: correlation with clinical, genetic and functional features. Eur J Hum Genet. 2006; 14(7):853-9. DOI: 10.1038/sj.ejhg.5201628. View

11.

Weller M, Stupp R, Reifenberger G, Brandes A, van den Bent M, Wick W . MGMT promoter methylation in malignant gliomas: ready for personalized medicine?. Nat Rev Neurol. 2009; 6(1):39-51. DOI: 10.1038/nrneurol.2009.197. View

12.

Boland C, Thibodeau S, Hamilton S, Sidransky D, Eshleman J, Burt R . A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998; 58(22):5248-57. View

13.

Barnetson R, Cartwright N, van Vliet A, Haq N, Drew K, Farrington S . Classification of ambiguous mutations in DNA mismatch repair genes identified in a population-based study of colorectal cancer. Hum Mutat. 2007; 29(3):367-74. DOI: 10.1002/humu.20635. View

14.

Viana-Pereira M, Lee A, Popov S, Bax D, Al-Sarraj S, Bridges L . Microsatellite instability in pediatric high grade glioma is associated with genomic profile and differential target gene inactivation. PLoS One. 2011; 6(5):e20588. PMC: 3102740. DOI: 10.1371/journal.pone.0020588. View

15.

Arita M, Zhong X, Min Z, Hemmi H, Shimatake H . Multiple sites required for expression in 5'-flanking region of the hMLH1 gene. Gene. 2003; 306:57-65. DOI: 10.1016/s0378-1119(03)00385-8. View

16.

Ganguly A, Rock M, Prockop D . Conformation-sensitive gel electrophoresis for rapid detection of single-base differences in double-stranded PCR products and DNA fragments: evidence for solvent-induced bends in DNA heteroduplexes. Proc Natl Acad Sci U S A. 1993; 90(21):10325-9. PMC: 47767. DOI: 10.1073/pnas.90.21.10325. View

17.

Jeuken J, Cornelissen S, Vriezen M, Dekkers M, Errami A, Sijben A . MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas. Lab Invest. 2007; 87(10):1055-65. DOI: 10.1038/labinvest.3700664. View

18.

Wehming F, Wiese B, Nakamura M, Bremer M, Karstens J, Meyer A . Malignant glioma grade 3 and 4: how relevant is timing of radiotherapy?. Clin Neurol Neurosurg. 2012; 114(6):617-21. DOI: 10.1016/j.clineuro.2011.12.024. View

19.

Allan J, Shorto J, Adlard J, Bury J, Coggins R, George R . MLH1 -93G>A promoter polymorphism and risk of mismatch repair deficient colorectal cancer. Int J Cancer. 2008; 123(10):2456-9. DOI: 10.1002/ijc.23770. View

20.

Esteller M . Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet. 2007; 16 Spec No 1:R50-9. DOI: 10.1093/hmg/ddm018. View